1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,137 | 0,171 | 10:43 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Cantargia Announces Changes in Number of Shares and Votes | 183 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / January 31, 2025 / Cantargia AB's (publ) ("Cantargia" or the "Company") (Nasdaq Stockholm:CANTA) today announced that the number of shares and votes in Cantargia AB... ► Artikel lesen | |
| 18.12.24 | Cantargia Publishes Strong Preclinical Effects and Clinical Monotherapy Results on Nadunolimab in Pancreatic Cancer in Journal for Immunotherapy of Cancer | 280 | ACCESS Newswire | LUND, SE / ACCESSWIRE / December 18, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced the publication of preclinical and clinical results using the IL1RAP... ► Artikel lesen | |
| 11.12.24 | Cantargia and GEICAM Present Updated Phase 1 Clinical Data and New Translational Results on Nadunolimab Treatment in Advanced Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium | 282 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / December 11, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported updated results from the phase 1b study in 15 advanced triple negative... ► Artikel lesen | |
| 02.12.24 | Extraordinary General Meeting in Cantargia AB | 193 | ACCESS Newswire | LUND, SE / ACCESSWIRE / December 02, 2024 / Cantargia (STO:CANTA) Cantargia's extraordinary general meeting on December 2, 2024, resolved to approve the board's resolution from November 6, 2024 to increase... ► Artikel lesen | |
| 02.12.24 | Cantargia AB: Extraordinary general meeting in Cantargia AB (publ) | 277 | GlobeNewswire (Europe) | Cantargia's extraordinary general meeting on December 2, 2024, resolved to approve the board's resolution from November 6, 2024 to increase the company's share capital through the issuance of new shares... ► Artikel lesen | |
| 02.12.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.12.2024 | 250 | Xetra Newsboard | Das Instrument F1S AU000000OAR8 OAR RESOURCES LTD. EQUITY wird cum Kapitalmassnahme gehandelt am 02.12.2024 und ex Kapitalmassnahme am 03.12.2024 The instrument F1S AU000000OAR8 OAR RESOURCES LTD. EQUITY... ► Artikel lesen | |
| CANTARGIA Aktie jetzt für 0€ handeln | |||||
| 29.11.24 | Cantargia Expands the CAN10 Phase 1 Clinical Program Building on Positive Results | 258 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / November 29, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported initiation of an expanded part of CAN10's phase 1 clinical study... ► Artikel lesen | |
| 15.11.24 | Cantargia Publishes Interim Report for Third Quarter 2024 | 205 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / November 15, 2024 / Cantargia (STO:CANTA) Cantargia AB's ("Cantargia") interim report for the period January until September 2024 is now available on the company's web page... ► Artikel lesen | |
| 13.11.24 | Cantargia Presents Nomination Committee Ahead of 2025 AGM | 195 | ACCESS Newswire | LUND, SE / ACCESSWIRE / November 13, 2024 / Cantargia (STO:CANTA) Cantargia AB (publ) hereby provides notification that the Nomination Committee (NC) has been appointed ahead of the 2025 Annual General... ► Artikel lesen | |
| 11.11.24 | Cantargia Results Showing Efficacy of CAN10 in Models of Myocarditis Published in Circulation: Heart Failure | 532 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / November 11, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today announced the publication of CAN10 results in disease models of myocarditis... ► Artikel lesen | |
| 06.11.24 | Notice of extraordinary general meeting in Cantargia AB | 265 | ACCESS Newswire | LUND, SE / ACCESSWIRE / November 6, 2024 / Cantargia (STO:CANTA) The shareholders of Cantargia AB (publ) are invited to the extraordinary general meeting on Monday, 2 December 2024, at 10.00 CET at... ► Artikel lesen | |
| 05.11.24 | Cantargia Presents Promising Preclinical Results on Nadunolimab With Antibody-Drug Conjugates at Major Immuno-Oncology Conference | 192 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / November 05, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported preclinical results on potential synergism between nadunolimab and... ► Artikel lesen | |
| 01.11.24 | Invitation to Presentation of Cantargia's Interim Report January - September 2024 | 262 | ACCESS Newswire | LUND, SE / ACCESSWIRE / November 01, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) invites investors, analysts and the press to a presentation of the interim report for... ► Artikel lesen | |
| 28.10.24 | Cantargia Reports New Results from Clinical Studies Investigating Nadunolimab in Several Forms of Cancer; Supporting Ongoing Strategies | 308 | ACCESS Newswire | LUND, SE / ACCESSWIRE / October 28, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB); (Nasdaq Stockholm:CANTA) today announced new clinical results from two nadunolimab combination therapy trials... ► Artikel lesen | |
| 11.10.24 | Cantargia Reports New Positive Results on Biomarkers and Safety in CAN10 Phase 1 Clinical Study | 279 | ACCESS Newswire | LUND, SE / ACCESSWIRE / October 11, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced new results from the CAN10 phase 1 clinical study. All nine groups... ► Artikel lesen | |
| 10.10.24 | Cantargia's Strong Phase 2 Clinical Data in Pancreatic Cancer with Nadunolimab Published in Clinical Cancer Research | 386 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / October 10, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced the publication of the results using nadunolimab (CAN04) combination... ► Artikel lesen | |
| 25.09.24 | Cantargia Presents New Results at EADV 2024 Highlighting the Potential of CAN10 Treatment in Dermatology | 268 | ACCESS Newswire | LUND, SE / ACCESSWIRE / September 25, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today presented data from preclinical experiments showing the high potential of the... ► Artikel lesen | |
| 14.09.24 | Cantargia Presents Positive Results at ESMO Congress 2024 Showing Benefit of Nadunolimab Combination Therapy in Cancer After Relapse on PD1-inhibitors | 534 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / September 14, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today presented data from two clinical trials of nadunolimab combination therapy... ► Artikel lesen | |
| 09.09.24 | Cantargia: New Data from Two Clinical Studies Strongly Support Nadunolimab Efficacy After Relapse on PD1-Inhibitors | 670 | ACCESS Newswire | LUND, SE / ACCESSWIRE / September 8, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported data from two clinical trials including nadunolimab combination therapy... ► Artikel lesen | |
| 28.08.24 | Cantargia Publishes Half-Year Report 2024 | 347 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / August 28, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced its interim report for January to June 2024."It has been an... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 113,10 | +0,18 % | BioNTech SE: BioNTech schließt Übernahme von Biotheus ab | Die Übernahme ist ein wichtiger Teil von BioNTech's Onkologie-Strategie, die darauf abzielt, BNT327 als tumorübergreifende (Pan-Tumor-) Technologieplattform für die Behandlung von fortgeschrittenen... ► Artikel lesen | |
| EVOTEC | 8,630 | +3,29 % | Commerzbank, Deutz, Evotec, Renk, Shell, Valneva - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| QIAGEN | 41,825 | -0,50 % | Qiagen NV-Aktie kann Vortagsniveau nicht halten (42,58 €) | An der Börse notiert die Aktie von Qiagen NV derzeit ein wenig leichter. Der jüngste Kurs betrug 42,58 Euro. Heute hat sich am Aktienmarkt das Wertpapier von Qiagen NV zwischenzeitlich um 0,73 Prozent... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 668,00 | -0,54 % | Nach monatelanger Talfahrt: Bayer-Partner Regeneron: Ist das das Ende? | © Foto: SOPA Images - picture allianceMonatelang kannte die Aktie von US-Biotechunternehmen Regeneron nur eine Richtung - nach unten. Am Dienstag beweisen die Käuferinnen und Käufer jedoch Mut.Um fast... ► Artikel lesen | |
| BRAIN BIOTECH | 2,960 | +1,02 % | BRAIN Biotech: Meilenstein - Ausgründung erhält frisches Kapital | Gute Neuigkeiten aus dem hessischen Zwingenberg: Der CRISPR-Spezialist Akribion Therapeutics, eine Ausgründung der BRAIN Biotech AG, erhält im Rahmen einer Seed-Finanzierungsrunde frische liquide Mittel... ► Artikel lesen | |
| SCORPIUS | 0,234 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| CARDIOL THERAPEUTICS | 1,352 | +0,60 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference | Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,062 | +3,32 % | Burcon NutraScience Corporation: Burcon Agrees to Terms with its Alliance Partner for a Protein Production Facility | Vancouver, British Columbia--(Newsfile Corp. - February 3, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development... ► Artikel lesen | |
| CSL | 163,58 | -0,15 % | Own CSL shares? Here's what to watch in next week's earnings update | ||
| MANNKIND | 5,400 | +0,41 % | MannKind Reports Encouraging 6-month Data From Phase 3 INHALE-1 Study | WASHINGTON (dpa-AFX) - MannKind Corporation (MNKD) Monday reported positive six-month results from its Phase 3 INHALE-1 study of Afrezza Inhalation Powder, a rapid-acting inhaled human insulin... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,650 | -0,72 % | Research and Markets: Europe Genome Sequencing Market Analysis and Forecasts 2024 & 2025-2033, Competition Synopsis of Eurofins Scientific, F. Hoffmann-La Roche, OncoDNA, Oxford Nanopore Technologies, and QIAGEN - ResearchAndMarkets.com | The "Europe Genome Sequencing Market: Focus on Product, End User, and Country Analysis and Forecast: 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe genome sequencing... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 7,382 | -1,91 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting | ||
| ADAPTIMMUNE THERAPEUTICS | 0,560 | +0,90 % | Adaptimmune Therapeutics PLC: Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor... ► Artikel lesen | |
| CODEXIS | 4,328 | +1,12 % | Codexis Aktie: Negative Entwicklungen? | Die Biotechnologie-Firma Codexis musste zum Monatsbeginn Februar 2025 einen erneuten Rückschlag verkraften. Der Aktienkurs des Enzymentwicklers fiel auf 4,04 EUR, was einem Tagesverlust von 0,25 Prozent... ► Artikel lesen | |
| TELO GENOMICS | 0,071 | +29,09 % | Telo Genomics mit SCHOCKIERENDER Prognose: Könnte die Aktie am Montag komplett kippen - Das müssen Sie unbedingt beachten! |
CANTARGIA AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,82 % bei einem Aktienkurs von 0,135 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANTARGIA AB finden Sie auf Wallstreet Online.
